Equillium (LTS:0A4D) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Short-Term Debt?

Equillium's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Equillium's annual Short-Term Debt increased from Dec. 2021 ($1.43 Mil) to Dec. 2022 ($5.71 Mil) but then declined from Dec. 2022 ($5.71 Mil) to Dec. 2023 ($0.00 Mil).

Equillium Short-Term Debt Historical Data

The historical data trend for Equillium's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Short-Term Debt Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

1.67

1.43

5.71

Equillium Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Equillium Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Equillium Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Equillium's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium Headlines

No Headlines